-
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab),
and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4
additional assets
-
The partnership will cover development and commercialization in the United States, Europe, and Canada, with
an option to expand to other territories
-
The partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with
Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring
additional important treatment options to patients worldwide
INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)--
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the
companies have entered into a global license, development, and commercialization agreement for up to six
potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar
candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing
Ilaris®2 (canakinumab).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001835078/en/
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory
registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global
markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for
expanding the partnership to other territories.
This agreement reinforces the long-standing and successful partnership between Samsung Bioepis and Teva, which
has already resulted in the successful commercialization of EPYSQLI® (eculizumab-aagh) in the U.S.
The companies have also expanded that agreement further to include OPUVIZ® (aflibercept) in Canada.
The expanded collaboration reflects a shared approach to combining complementary capabilities for broadening
access to biosimilar medicines across global markets.
“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates. This
agreement marks another milestone in our shared journey to improve patient access to life-changing medicines,”
said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “At Samsung Bioepis, we will
continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and
widening their availability for patients and healthcare systems across the world.”
Richard Francis, President and CEO of Teva said, “Biosimilars are an increasingly important part of our Pivot to
Growth strategy and our ambition to transform into a leading biopharmaceutical company. This global
multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our
pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S. By combining
a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our
leadership position in biosimilars and our ability to bring more treatment options to patients around the
world.”
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is
accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung
Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung
Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that
cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology,
neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative
biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to
bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing
complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’
needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or
achievements to differ significantly from that expressed or implied by such forward-looking statements. You can
identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,”
“estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and
expression in connection with any discussion of future operating or financial performance. Important factors
that could cause or contribute to such differences include risks relating to: our ability to successfully
execute the license, development and commercialization agreement with Samsung Bioepis; our ability to
successfully compete in the marketplace, including our ability to develop and commercialize additional
pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand
our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and
biosimilar portfolio, whether organically or through business development, and to sustain and focus our
portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second
quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the
section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking
statements speak only as of the date on which they are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
1 Fasenra is a trademark of AstraZeneca AB.
2 Ilaris is a trademark of Novartis AG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261001835078/en/
MEDIA CONTACT
Samsung Bioepis Media Inquiries:
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com
Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:
TevaIR@Tevapharm.com
Source: Samsung Bioepis Co., Ltd.